Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Sales: 2022-2025

Historic Return on Sales for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Sep 2025 value amounting to -1.86%.

  • Phathom Pharmaceuticals' Return on Sales rose 1105.00% to -1.86% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.86%, marking a year-over-year increase of 1105.00%. This contributed to the annual value of -6.05% for FY2024, which is 28926.00% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Return on Sales of -1.86% as of Q3 2025, which was up 35.58% from -2.89% recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Return on Sales ranged from a high of 14.38% in Q1 2024 and a low of -12.92% during Q3 2024.
  • For the 3-year period, Phathom Pharmaceuticals' Return on Sales averaged around 0.88%, with its median value being 1.36% (2023).
  • The largest annual percentage gain for Phathom Pharmaceuticals' Return on Sales in the last 5 years was 1,105bps (2025), contrasted with its biggest fall of 1,861bps (2025).
  • Over the past 4 years, Phathom Pharmaceuticals' Return on Sales (Quarterly) stood at 7.24% in 2022, then fell by 11bps to 7.13% in 2023, then crashed by 1,318bps to -6.05% in 2024, then spiked by 1,105bps to -1.86% in 2025.
  • Its Return on Sales was -1.86% in Q3 2025, compared to -2.89% in Q2 2025 and -4.22% in Q1 2025.